
Mark A Riddle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11687368/publications.pdf Version: 2024-02-01



Μλρκ Δ Ρισσιε

#	Article	IF	CITATIONS
1	The Yale Global Tic Severity Scale: Initial Testing of a Clinician-Rated Scale of Tic Severity. Journal of the American Academy of Child and Adolescent Psychiatry, 1989, 28, 566-573.	0.5	1,906
2	Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 844-852.	0.5	1,725
3	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
4	Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. New England Journal of Medicine, 2001, 344, 1279-1285.	27.0	584
5	The relationship of obsessive–compulsive disorder to possible spectrum disorders: results from a family study. Biological Psychiatry, 2000, 48, 287-293.	1.3	471
6	Psychotropic Practice Patterns for Youth. JAMA Pediatrics, 2003, 157, 17.	3.0	470
7	Prevalence and correlates of hoarding behavior in a community-based sample. Behaviour Research and Therapy, 2008, 46, 836-844.	3.1	360
8	Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 222-229.	0.5	347
9	Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 1062-1069.	0.5	344
10	Obsessive Compulsive Disorder in Children and Adolescents: Phenomenology and Family History. Journal of the American Academy of Child and Adolescent Psychiatry, 1990, 29, 766-772.	0.5	262
11	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	3.5	241
12	Personality disorders and normal personality dimensions in obsessive-compulsive disorder. British Journal of Psychiatry, 2000, 177, 457-462.	2.8	198
13	Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, 30, 179-186.	0.5	195
14	Hoarding in obsessive–compulsive disorder: Results from the OCD Collaborative Genetics Study. Behaviour Research and Therapy, 2007, 45, 673-686.	3.1	189
15	Sudden Death in Children Receiving Norpramin®: A Review of Three Reported Cases and Commentary. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, 30, 104-108.	0.5	186
16	The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: the Hopkins OCD family study. Biological Psychiatry, 2001, 50, 559-565.	1.3	177
17	Another Sudden Death in a Child Treated with Desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 1993, 32, 792-797.	0.5	173
18	Fluoxetine Treatment of Children and Adolescents with Tourette's and Obsessive Compulsive Disorders: Preliminary Clinical Experience. Journal of the American Academy of Child and Adolescent Psychiatry, 1990, 29, 45-48.	0.5	167

#	Article	IF	CITATIONS
19	The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 264-278.e2.	0.5	162
20	Somatic Symptoms in Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1179-1187.	0.5	155
21	Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology, 1995, 12, 73-86.	5.4	150
22	Familiality of Factor Analysis-Derived YBOCS Dimensions in OCD-Affected Sibling Pairs from the OCD Collaborative Genetics Study. Biological Psychiatry, 2007, 61, 617-625.	1.3	149
23	Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. American Journal of Psychiatry, 2007, 164, 290-300.	7.2	147
24	Preventing Onset of Anxiety Disorders in Offspring of Anxious Parents: A Randomized Controlled Trial of a Family-Based Intervention. American Journal of Psychiatry, 2015, 172, 1207-1214.	7.2	142
25	Further development of YBOCS dimensions in the OCD Collaborative Genetics Study: Symptoms vs. categories. Psychiatry Research, 2008, 160, 83-93.	3.3	138
26	Significant Linkage to Compulsive Hoarding on Chromosome 14 in Families With Obsessive-Compulsive Disorder: Results From the OCD Collaborative Genetics Study. American Journal of Psychiatry, 2007, 164, 493-499.	7.2	132
27	Clinical Presentation of Attention-Deficit/Hyperactivity Disorder in Preschool Children: The Preschoolers with Attention-Deficit/Hyperactivity Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 547-562.	1.3	124
28	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	7.2	117
29	Fluvoxamine Open-Label Treatment of Adolescent Inpatients with Obsessive-Compulsive Disorder or Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 342-348.	0.5	104
30	Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 1990, 1, 193-198.	1.3	91
31	Corpus callosum morphology from magnetic resonance images in Tourette's syndrome. Psychiatry Research - Neuroimaging, 1994, 55, 85-99.	1.8	90
32	Antipsychotic Treatment Among Youth in Foster Care. Pediatrics, 2011, 128, e1459-e1466.	2.1	89
33	Anxiolytics, Adrenergic Agents, and Naltrexone. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 546-556.	0.5	86
34	Parent versus Teacher Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 605-619.	1.3	85
35	Comparison of Increasingly Detailed Elicitation Methods for the Assessment of Adverse Events in Pediatric Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 1488-1496.	0.5	83
36	Treatment of Pediatric Anxiety Disorders: An Open-Label Extension of the Research Units on Pediatric Psychopharmacology Anxiety Study. Journal of Child and Adolescent Psychopharmacology, 2002, 12, 175-188.	1.3	82

#	Article	IF	CITATIONS
37	The treatment of anxiety disorders in children and adolescents. Biological Psychiatry, 1999, 46, 1567-1578.	1.3	80
38	Comprehensive familyâ€based association study of the glutamate transporter gene SLC1A1 in obsessiveâ€compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 472-477.	1.7	78
39	Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology, 1997, 7, 75-85.	1.3	74
40	Randomized, Placebo-Controlled, Crossover Study of Methylphenidate for Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers with Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 329-339.	1.3	73
41	The Utility of Clinicians Ratings of Anxiety Using the Pediatric Anxiety Rating Scale (PARS). Child and Youth Care Forum, 2011, 40, 93-105.	1.6	72
42	Review of Safety Assessment Methods Used in Pediatric Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 627-633.	0.5	71
43	The OCD collaborative genetics study: Methods and sample description. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 201-207.	1.7	69
44	Metformin addâ€on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry, 2020, 19, 69-80.	10.4	68
45	Methylphenidate Effects on Functional Outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 581-592.	1.3	67
46	Comorbidity Moderates Response to Methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 563-579.	1.3	67
47	Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 119-126.	1.3	66
48	Neuroimaging correlates of anxiety after pediatric traumatic brain injury. Biological Psychiatry, 2004, 55, 208-216.	1.3	65
49	Factor analysis of the Yale–Brown Obsessive Compulsive Scale in a family study of obsessive–compulsive disorder. Depression and Anxiety, 2007, 24, 130-138.	4.1	65
50	The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology, 2007, 191, 67-86.	3.1	64
51	New onset obsessive-compulsive symptoms in children and adolescents with severe traumatic brain injury. Depression and Anxiety, 2008, 25, 398-407.	4.1	62
52	Human basal ganglia volume asymmetries on magnetic resonance images. Magnetic Resonance Imaging, 1993, 11, 493-498.	1.8	61
53	Pediatric loss of control eating syndrome: Association with attentionâ€deficit/hyperactivity disorder and impulsivity. International Journal of Eating Disorders, 2015, 48, 580-588.	4.0	61
54	Anxiety After Severe Pediatric Closed Head Injury. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 148-156.	0.5	58

#	Article	IF	CITATIONS
55	Clinical correlates of recurrent major depression in obsessive-compulsive disorder. Depression and Anxiety, 2004, 20, 86-91.	4.1	58
56	Pharmacotherapyin Children and Adolescents With Obsessive-Compulsive Disorder. Child and Adolescent Psychiatric Clinics of North America, 1999, 8, 617-634.	1.9	56
57	Searching for Moderators and Mediators of Pharmacological Treatment Effects in Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 13-21.	0.5	55
58	Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 593-603.	1.3	55
59	How Can We Improve the Assessment of Safety in Child and Adolescent Psychopharmacology?. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 634-641.	0.5	54
60	Sertraline for Major Depression in Children and Adolescents: Preliminary Clinical Experience. Journal of Child and Adolescent Psychopharmacology, 1995, 5, 13-27.	1.3	51
61	Pediatric Psychopharmacology. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2001, 42, 73-90.	5.2	51
62	Child/Adolescent Anxiety Multimodal Study: EvaluatingÂSafety. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 180-190.	0.5	50
63	Factor Structure of Parent- and Teacher-Rated Attention-Deficit/Hyperactivity Disorder Symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 621-633.	1.3	49
64	The Relevance of Prolonged QTc Measurement to Pediatric Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 642-650.	0.5	48
65	Psychostimulants in Preschool Children With Attention-Deficit/Hyperactivity Disorder: Clinical Evidence From a Developmental Disorders Institution. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 516-524.	0.5	47
66	Association between binge eating and attentionâ€deficit/hyperactivity disorder in two pediatric community mental health clinics. International Journal of Eating Disorders, 2015, 48, 505-511.	4.0	47
67	Pharmacologic Treatment of Anxiety Disorders in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America, 2000, 9, 119-133.	1.9	45
68	The association between parental bonding and obsessive compulsive disorder in offspring at high familial risk. Journal of Affective Disorders, 2008, 111, 31-39.	4.1	45
69	The Pharmacologic Treatment of Tic Disorders. Child and Adolescent Psychiatric Clinics of North America, 1995, 4, 197-216.	1.9	44
70	Cognitive functioning in compulsive hoarding. Journal of Anxiety Disorders, 2011, 25, 1139-1144.	3.2	43
71	The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biological Psychiatry, 2004, 56, 3-9.	1.3	41
72	Pharmacotherapy of Tourette's Syndrome and Associated Disorders. Psychiatric Clinics of North America, 1992, 15, 109-129.	1.3	41

#	Article	IF	CITATIONS
73	The Relationship of Pathologic Skin Picking to Obsessive-Compulsive Disorder. Journal of Nervous and Mental Disease, 2001, 189, 193-195.	1.0	40
74	Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: Age and sex effects and individual variability. Biological Psychiatry, 1986, 21, 69-83.	1.3	37
75	Abnormal magnetic resonance imaging T2 relaxation time asymmetries in Tourette's syndrome. Psychiatry Research - Neuroimaging, 1994, 55, 205-221.	1.8	36
76	Sex-specific clinical correlates of hoarding in obsessive-compulsive disorder. Behaviour Research and Therapy, 2008, 46, 1040-1046.	3.1	35
77	Exome sequencing in obsessive–compulsive disorder reveals a burden of rare damaging coding variants. Nature Neuroscience, 2021, 24, 1071-1076.	14.8	35
78	Developing Methodologies for Monitoring Long-Term Safety of Psychotropic Medications in Children: Report on the NIMH Conference, September 25, 2000. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 651-655.	0.5	33
79	A Guide for Managing Acute Aggressive Behavior of Youths in Residential and Inpatient Treatment Facilities. Psychiatric Services, 2003, 54, 1357-1363.	2.0	33
80	Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 999-1007.e4.	0.5	33
81	Hoarding in children and adolescents with obsessive–compulsive disorder. Journal of Obsessive-Compulsive and Related Disorders, 2014, 3, 325-331.	1.5	31
82	Pharmacological Treatment of Childhood Obsessive-Compulsive Disorder: From Theory to Practice. Journal of Clinical Child and Adolescent Psychology, 2001, 30, 67-79.	3.4	30
83	Improving the Management of Acute Aggression in State Residential and Inpatient Psychiatric Facilities for Youths. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 897-905.	0.5	30
84	Selective Serotonin Reuptake Inhibitor-Induced Apathy: A Pediatric Case Series. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 227-233.	1.3	30
85	Pharmacotherapy of the Preschool ADHD Treatment StudyÂ(PATS) Children Growing Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 550-556.	0.5	30
86	An investigation of doubt in obsessive–compulsive disorder. Comprehensive Psychiatry, 2017, 75, 117-124.	3.1	30
87	Psychosis in children: diagnosis and treatment. Dialogues in Clinical Neuroscience, 2001, 3, 79-92.	3.7	30
88	Tourette's Syndrome: Clinical and Neurochemical Correlates. Journal of the American Academy of Child and Adolescent Psychiatry, 1988, 27, 409-412.	0.5	26
89	Parental bonding and hoarding in obsessive–compulsive disorder. Comprehensive Psychiatry, 2017, 73, 43-52.	3.1	25
90	Pharmacokinetics in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America, 1995, 4, 59-75.	1.9	24

#	Article	IF	CITATIONS
91	Separation anxiety disorder in OCD. Depression and Anxiety, 2011, 28, 256-262.	4.1	24
92	ADHD and executive functioning deficits in OCD youths who hoard. Journal of Psychiatric Research, 2016, 82, 141-148.	3.1	24
93	THE NEW ANTIDEPRESSANTS. Pediatric Clinics of North America, 1998, 45, 1137-1155.	1.8	23
94	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	4.8	23
95	Obsessive-compulsive disorder in children and adolescents. International Review of Psychiatry, 1997, 9, 83-98.	2.8	22
96	Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1008-1019.	0.5	22
97	Selective serotonin reuptake inhibitors for children and adolescents. Current Psychiatry Reports, 2000, 2, 117-123.	4.5	21
98	ls Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?. Movement Disorders, 2021, 36, 1899-1910.	3.9	21
99	Early Identification of Seclusion and Restraint Patterns During Adolescents' Course of Residential Treatment. Residential Treatment for Children and Youth, 2010, 27, 160-174.	0.9	20
100	OBSESSIVE-COMPULSIVE PERSONALITY DISORDER: EVIDENCE FOR TWO DIMENSIONS. Depression and Anxiety, 2016, 33, 128-135.	4.1	20
101	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child and Adolescent Psychiatry and Mental Health, 2013, 7, 31.	2.5	19
102	Low CSF 5HIAA and obsessions of violence: Report of two cases. Psychiatry Research, 1990, 33, 95-99.	3.3	18
103	Do all obsessive-compulsive disorder subtypes respond to medication?. International Review of Psychiatry, 2008, 20, 189-193.	2.8	18
104	Plasma-free homovanillic acid: Within- and across-day stability in children and adults with tourette's syndrome. Life Sciences, 1987, 40, 2145-2151.	4.3	13
105	Genome Wide Association Study (GWAS) between Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD). Frontiers in Molecular Neuroscience, 2017, 10, 83.	2.9	13
106	Trichotillomania comorbidity in a sample enriched for familial obsessive-compulsive disorder. Comprehensive Psychiatry, 2019, 94, 152123.	3.1	13
107	Pediatric Psychopharmacology. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2001, 42, 73-90.	5.2	13
108	Plasma MHPG: Within- and across-day stability in children and adults with tourette's syndrome. Biological Psychiatry, 1988, 24, 391-398.	1.3	12

#	Article	IF	CITATIONS
109	Psychiatric Pharmacoepidemiology for Children. Child and Adolescent Psychiatric Clinics of North America, 1995, 4, 77-95.	1.9	12
110	Antipsychotic Treatment Patterns and Aggressive Behavior Among Adolescents in Residential Facilities. Journal of Behavioral Health Services and Research, 2013, 40, 97-110.	1.4	12
111	Brief debrisoquin administration to assess central dopaminergic function in children. Life Sciences, 1986, 38, 1041-1048.	4.3	11
112	Improving the methods for evaluating the safety of psychotropic medications in children and adolescents. Current Therapeutic Research, 2001, 62, 873-884.	1.2	11
113	New Findings from the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 543-546.	1.3	10
114	Childhood Obsessive-Compulsive Disorder Presenting as Schizophrenia Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 395-401.	1.3	10
115	The Iron Status of Children and Youth in a Community Mental Health Clinic is Lower than that of a National Sample. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 91-100.	1.3	10
116	Clinical correlates and genetic linkage of social and communication difficulties in families with obsessive–compulsive disorder: Results from the OCD Collaborative Genetics Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 326-336.	1.7	10
117	Self-reported executive function and hoarding in adults with obsessive-compulsive disorder. Comprehensive Psychiatry, 2018, 81, 53-59.	3.1	10
118	Obsessive-Compulsive Disorder in Children and Adolescents. CNS Drugs, 1999, 12, 257-277.	5.9	9
119	Preventing the Onset of Anxiety Disorders in Offspring of Anxious Parents: A Six-Year Follow-up. Child Psychiatry and Human Development, 2021, 52, 751-760.	1.9	9
120	Effects of Source of DNA on Genotyping Success Rates and Allele Percentages in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 635-645.	1.3	8
121	General personality dimensions, impairment and treatment response in obsessive–compulsive disorder. Personality and Mental Health, 2020, 14, 186-198.	1.2	6
122	PAROXETINE AND THE FDA. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 128-130.	0.5	5
123	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 364-375.	1.3	4
124	Two Times Four Is Four: OCD Dimensions, Classes, and Categories. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 731-733.	0.5	3
125	Antipsychotic-Induced Psychotic-Like Syndrome and Pathological Smiling in an Adolescent. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 92-95.	1.3	3
126	Two Times Four Is Four. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 731-733.	0.5	3

#	Article	IF	CITATIONS
127	Neurotransmitter Assessment in Neuropsychiatric Disorders of Childhood. , 1990, , 33-59.		3
128	Neuroleptic Malignant Syndrome in Children and Adolescents: Time to Stop, Look, and Listen. Journal of Child and Adolescent Psychopharmacology, 1992, 2, 155-156.	1.3	2
129	BENIGN U-WAVE MISTAKEN FOR QTc PROLONGATION. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 621.	0.5	2
130	Commentary by an Academic Child and Adolescent Psychiatrist. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 300-302.	1.3	2
131	Introduction: Issues and viewpoints in pediatric psychopharmacology. International Review of Psychiatry, 2008, 20, 119-120.	2.8	2
132	A Practical and Effective Primary Care Intervention for Treating Adolescent Depression. JAMA - Journal of the American Medical Association, 2014, 312, 797.	7.4	2
133	Pediatric psychopharmacology in primary care: a conceptual framework. Adolescent Medicine: State of the Art Reviews, 2013, 24, 371-90, vii.	0.2	2
134	Venlafaxine extended release in pediatric anxiety and depression. Pediatric Health, 2008, 2, 279-288.	0.3	1
135	Title is missing!. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, 30, 849-850.	0.5	0
136	Attention-deficit hyperactivity disorder: a view from the USA. Nature Clinical Practice Neurology, 2008, 4, 118-119.	2.5	0
137	Cost-benefit Analysis of the Coping and Promoting Strength Program. Prevention Science, 2021, 22, 1096-1107.	2.6	0